INO Inovio Pharmaceuticals, Inc. stock chart & analysis
Conviction 36HealthcareScan · Fri, Oct 30, 2026Inovio Pharmaceuticals, Inc. (INO) closed at $0.6000 (-22.26%) on Oct 30, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 27, RS Rating 7, -77.9% from its 52-week high, -65.5% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Price chart, 63 bars from Tue, Aug 4, 2026 to Fri, Oct 30, 2026. Last close $0.6000, high $1.45, low $0.5972.
Why INO moved
From the StockSetups movers recaps that covered INO, newest first. A recap states what was known that day.
- After hours+241.7%
The FDA granted accelerated approval to Voceryq (INO-3107), Inovio's treatment for recurrent respiratory papillomatosis, a rare disease. Stocktwits described it as the company's first approved product.
After-Hours Movers Oct 30, 2026: Why INO, CLRO, CAPR Jumped →
Financials as of Tue, Jun 30, 2026 · quarterly.
INO technical analysis
Trend
INO is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 47.3% below the 50-day ($1.14) and 52.5% below the 200-day ($1.26). ADX(14) at 28 points to a strong, established trend. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 27, in oversold territory. The MACD histogram is negative. Its RS Rating of 7 puts its weighted 12-month performance ahead of about 7% of the US market.
Volume and volatility
Volume on the latest session ran 7.0× its 20-day average. It trades about $5.0M a day on average. ATR(14) is $0.1295, 21.6% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.51) shows distribution.
Key levels
The chart pattern's support is $0.8656 and its resistance $1.39. The 52-week range is $0.5632 to $2.72; price is 77.9% below the high and 6.5% above the low. The VWAP anchored at the 52-week high is $1.17, above price.
Performance
INO returned -33.1% (1 week), -50.4% (1 month), -13.9% (3 months), -45.5% (6 months), -75.3% (1 year), -65.5% (year to date).
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Pharmaceutical Preparations · Listed 1998 · 112 employees
Recent news
- Inovio Pharmaceuticals (INO) Soars 280% After FDA Approves VocerGuruFocus · Fri, Oct 30, 2026
- PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA ApprovalStocktwits · Fri, Oct 30, 2026
- INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)Yahoo Finance · Fri, Oct 30, 2026
- INOVIO gets FDA accelerated approval for VOCERYQ | INO Stock NewsStock Titan · Fri, Oct 30, 2026
- Why is Inovio Pharmaceuticals stock surging today? By Investing.comInvesting.com UK · Fri, Oct 30, 2026
- Inovio surges 280% following FDA approval of Voceryq for rare disease (INO:NASDAQ)Seeking Alpha · Fri, Oct 30, 2026
- US FDA approves Inovio's treatment for rare throat disease; shares surgeReuters · Fri, Oct 30, 2026
- When the Price of (INO.UN) Talks, People Listen (INO.UN:CA)Stock Traders Daily · Fri, Oct 30, 2026
- Inovio Pharmaceuticals stock faces FDA decision for INO-3107ad-hoc-news.de · Fri, Oct 30, 2026
- Inovalis Real Estate Investment Trust (INO-UN.TO) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada · Thu, Oct 29, 2026
Insider activity
SEC Form 4 transactions in INO
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Weiner David B. Director · Common Stock Options · 2026-05-20 | Grant | 41.8K | $0 | 2026-05-20 | 2026-05-21 |
Miller Ann Calby Director · Common Stock Options · 2026-05-20 | Grant | 41.8K | $0 | 2026-05-20 | 2026-05-21 |
Humeau Laurent Chief Scientific Officer · Common Stock · 2026-05-20 | Tax | 2.16K | $3K | 2026-05-20 | 2026-05-21 |
Shea Jacqueline Elizabeth Chief Executive Officer · Common Stock · 2026-05-20 | Tax | 12.31K | $15K | 2026-05-20 | 2026-05-21 |
Shea Jacqueline Elizabeth Chief Executive Officer · Common Stock · 2026-05-20 | Exercise | 28.3K | — | 2026-05-20 | 2026-05-21 |
Sumner Michael John Chief Medical Officer · Restricted Stock Unit · 2026-05-20 | Exercise | 9.45K | $0 | 2026-05-20 | 2026-05-21 |
Sumner Michael John Chief Medical Officer · Common Stock · 2026-05-20 | Tax | 2.69K | $3K | 2026-05-20 | 2026-05-21 |
Zoth Lota S. Director · Common Stock Options · 2026-05-20 | Grant | 41.8K | $0 | 2026-05-20 | 2026-05-21 |
YARNO WENDY L Director · Restricted Stock Unit · 2026-05-20 | Grant | 34.2K | $0 | 2026-05-20 | 2026-05-21 |
KIES PETER CFO · Common Stock · 2026-05-20 | Exercise | 8.7K | — | 2026-05-20 | 2026-05-21 |
SEC filings
EDGAR filings in INO · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.